128.63

0.69% -0.90

After Hours: 128.63

Palvella Therapeutics Inc (PVLA)

Overview News Price History Discussions Forecast

Palvella Therapeutics Inc stock is traded at $128.63, with a volume of 165.30K. It is down -0.69% in the last 24 hours and up +5.38% over the past month. Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Previous Close:

$129.53

Open:

$129.75

24h Volume:

165.30K

Relative Volume:

0.54

Market Cap:

$1.84B

Revenue:

$1.30M

Net Income/Loss:

$-41.72M

P/E Ratio:

-34.70

EPS:

-3.7071

Net Cash Flow:

$-25.01M

1W Performance:

+4.43%

1M Performance:

+5.38%

6M Performance:

+68.56%

1Y Performance:

+437.53%

1-Day Range:

$125.61

$133.33

1-Week Range:

$120.34

$134.01

52-Week Range:

$20.20

$151.18

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name

Palvella Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(484) 253-1461

Address

353 W. LANCASTER AVENUE, WAYNE

Employee

Twitter

Next Earnings Date

2026-03-31

Latest SEC Filings

PVLA's Discussions on Twitter

Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PVLA Palvella Therapeutics Inc	128.63	1.85B	1.30M	-41.72M	-25.01M	-3.7071
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Initiated	Mizuho	Outperform
Dec-05-25	Initiated	BTIG Research	Buy
Dec-04-25	Initiated	Craig Hallum	Buy
Nov-19-25	Upgrade	Raymond James	Outperform → Strong Buy
Sep-09-25	Initiated	Oppenheimer	Outperform
Aug-06-25	Initiated	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Apr-09-25	Initiated	Chardan Capital Markets	Buy
Mar-26-25	Initiated	Stifel	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Feb-20-25	Initiated	Canaccord Genuity	Buy
Feb-05-25	Initiated	TD Cowen	Buy
Dec-26-24	Initiated	H.C. Wainwright	Buy
Dec-18-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform
Mar-19-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Initiated	Jefferies	Buy
Jan-16-18	Reiterated	H.C. Wainwright	Buy
May-30-17	Initiated	Rodman & Renshaw	Buy
Aug-05-16	Resumed	ROTH Capital	Buy
Aug-12-15	Initiated	JMP Securities	Mkt Outperform
Jul-27-15	Initiated	Oppenheimer	Outperform
Jul-22-15	Initiated	ROTH Capital	Buy

View All

Palvella Therapeutics Inc Stock (PVLA) Latest News

12:03 PM

Palvella reports 2025 results, advances QTORIN drug pipeline - MSN

12:03 PM

Apr 14, 2026

Palvella Appoints Kent Taylor as Senior Vice President of Sales - MyChesCo

Apr 14, 2026

Apr 13, 2026

Palvella Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Address, and Key Information - Minichart

Apr 13, 2026

Palvella Therapeutics appoints John Doux to board of directors By Investing.com - Investing.com South Africa

Apr 13, 2026

Palvella Therapeutics appoints John Doux, M.D., to board of directors By Investing.com - Investing.com South Africa

Apr 13, 2026

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors - Bitget

Apr 13, 2026

Palvella Therapeutics appoints John Doux, M.D., to board of directors - Investing.com

Apr 13, 2026

Palvella Therapeutics Adds Independent Dermatology Expert to Board - TipRanks

Apr 13, 2026

Palvella Therapeutics Appoints Dr. John D. Doux to Board of Directors to Advance Rare Disease Initiatives - Quiver Quantitative

Apr 13, 2026

Form 8-KCurrent report - ADVFN

Apr 13, 2026

Apr 11, 2026

Palvella Therapeutics (PVLA) price target increased by 15.78% to 224.97 - MSN

Apr 11, 2026

Apr 10, 2026

Volatility Watch: How does Palvella Therapeutics Inc compare to its peersEarnings Growth Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Apr 10, 2026

Apr 08, 2026

Palvella appoints McDonough as SVP of market access, patient services - MSN

Apr 08, 2026

PVLA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026